Non-Small Cell Lung Cancer (NSCLC) Market to Witness Upsurge in Growth During the Study Period (2019-2032), Evaluates DelveInsight

The market size of Non-Small Cell Lung Cancer (NSCLC) is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as novartis Pharmaceuticals, Novartis Pharmaceuticals, AbbVie, Janssen Pharmaceuticals, Xcovery, Eli Lilly and Company Sanofi, Pfizer, Astellas Pharma/Seattle Genetics, Takeda Pharmaceuticals, Novartis, Merck/Pfizer, Mirati Therapeutics/Bristol-Myers Squibb/Beigene, Merck/GlaxoSmithKline, Amgen, Incyte Corporation.

[Nevada, United States] - DelveInsight's "Non-Small Cell Lung Cancer (NSCLC) Market Insights, Epidemiology, and Market Forecast 2032." report offers a detailed examination of Non-Small Cell Lung Cancer (NSCLC), covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the Non-Small Cell Lung Cancer (NSCLC) Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; https://www.delveinsight.com/report-store/non-small-cell-lung-carcinoma-nsclc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Key Findings from the Non-Small Cell Lung Cancer (NSCLC) Market Report:
The Non-Small Cell Lung Cancer (NSCLC) market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2019-2032).
In September, 2024: AstraZeneca announced that a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of durvalumab + tremelimumab combination therapy versus platinum-based SoC chemotherapy in the first-line treatment of patients with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type advanced or metastatic NSCLC.
In September, 2024: Novartis Pharmaceuticals announced that their Phase 2 study will compare JDQ443 as monotherapy to docetaxel in participants with advanced non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation who have been previously treated with a platinum-based chemotherapy and immune checkpoint inhibitor therapy either in sequence or in combination.
In August: AstraZeneca announced that a Phase I/II study designed to evaluate if experimental anti-TIGIT/anti-PD-1 bispecific antibody rilvegostomig (AZD2936) is safe, tolerable and efficacious in participants with Advanced or Metastatic Non-small Cell Lung Cancer.
In August, 2024: Astex Pharmaceuticals, Inc. announced that the purpose of their study is to evaluate the safety and potential benefit of combination amuvatinib with standard of care chemotherapy treatment (platinum and etoposide) in small cell lung cancer (SCLC) subjects.
In August, 2024: Merck Sharp & Dohme LLC announced that the goal of this study is to learn if people who receive vibostolimab and pembrolizumab live longer overall and without the cancer getting worse than people who receive pembrolizumab alone.
In August, 2024: Mirati Therapeutics Inc. announced that their study will evaluate the efficacy of two dosing regimens of adagrasib (600 mg BID versus 400 mg BID) in patients with NSCLC with KRAS G12C mutation.
The American Cancer Society's estimated that around 238,340 new cases of lung cancer (117,550 in menand 120,790 in women) will be diagnosed in 2023. The society also reported that most lung cancer statisticsinclude both small cell lung cancer and non-small cell lung cancer. In general, about 10% to 15% of all lungcancers are SCLC, and about 80% to 85% are NSCLC.
As per the American Lung Cancer Association, the most frequent biomarkers that appeared in testing wereEGFR (64%), ALK (60%), PD-L1 (48%), ROS1 (46%), BRAF (40%), MET (35%), KRAS (29%), RET (22%), HER2(21%), and PIK3CA (20%). These biomarkers also comprise some of the most common biomarkers, alongwith neurotrophic tropomyosin kinase receptors (NTRK), found in patients with adenocarcinoma, a subtypeof NSCLC.
Key Non-Small Cell Lung Cancer (NSCLC) Companies are as follows: Novartis Pharmaceuticals, Novartis Pharmaceuticals, AbbVie, Janssen Pharmaceuticals, Xcovery, Eli Lilly and Company Sanofi, Pfizer, Astellas Pharma/Seattle Genetics, Takeda Pharmaceuticals, Novartis, Merck/Pfizer, Mirati Therapeutics/Bristol-Myers Squibb/Beigene, Merck/GlaxoSmithKline, Amgen, Incyte Corporation.
Key Non-Small Cell Lung Cancer (NSCLC) Therapies are as follow: Nazartinib/EGF816, Capmatinib/INC280, Telisotuzumab Vedotin, JNJ-61186372/JNJ-6372, Ensartinib/X-396, Selpercatinib (LY3527723/LOXO-292), SAR408701, Braftovi/encorafinib + Mektovi/binimetinib, PADCEV (enfortumab vedotin/ASG-22ME), TAK-788, Canakinumab/(ACZ885), BAVENCIO (Avelumab), Veliparib, Sitravatinib (MGCD516), M7824, AMG 510, INCMGA00012 (MGA012), Romiplostim, TEPMETKO (tepotinib).
Launching multiple stage Non-Small Cell Lung Cancer (NSCLC) pipeline products is expected to revolutionize market dynamics, further propelling market growth.

Dive into our detailed Non-Small Cell Lung Cancer (NSCLC) market research report to uncover actionable insights, industry forecasts, and competitive analysis @ https://www.delveinsight.com/sample-request/non-small-cell-lung-carcinoma-nsclc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Non-Small Cell Lung Cancer (NSCLC) Overview:
NSCLC is the most common type of lung cancer accounted for approximately 85% of all lung cancers.However, NSCLC metastasizes to other organs slower in comparison to SCLC, and microscopically, SCLC iscomposed of much smaller cells. NSCLC is mainly subcategorized into adenocarcinomas, squamous cell carcinomas, large cell carcinomasandseveral other types that occur less frequently include adenosquamous carcinomas, andsarcomatoid carcinomas. NSCLC can be located in the mid chest, but it is often also found in other parts of the lung too. Even though NSCLCs are associated with cigarette smoking, adenocarcinomas may also be found in patients who havenever smoked.

Non-Small Cell Lung Cancer (NSCLC) Drugs Uptake and Pipeline Development Activities:
The drugs uptake section focuses on the rate of uptake of potential drugs recently launched or expected to be launched during the study period. The report covers market uptake by drugs, patient uptake by therapies, and sales of each drug. Additionally, it provides insights into Non-Small Cell Lung Cancer (NSCLC) Pipeline Development Activities, analyzing therapeutic candidates in various stages and key companies involved.

For more information about Non-Small Cell Lung Cancer (NSCLC) companies working in the treatment market, visit: https://www.delveinsight.com/sample-request/non-small-cell-lung-carcinoma-nsclc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Non-Small Cell Lung Cancer (NSCLC) Therapies and Key Companies:
Nazartinib/EGF816: Novartis Pharmaceuticals
Capmatinib/INC280: Novartis Pharmaceuticals
Telisotuzumab Vedotin: AbbVie
JNJ-61186372/JNJ-6372: Janssen Pharmaceuticals
Ensartinib/X-396: Xcovery
Selpercatinib (LY3527723/LOXO-292): Eli Lilly and Company
SAR408701: Sanofi
Braftovi/encorafinib + Mektovi/binimetinib: Pfizer
PADCEV (enfortumab vedotin/ASG-22ME): Astellas Pharma/Seattle Genetics
TAK-788: Takeda Pharmaceuticals
Canakinumab/(ACZ885): Novartis
BAVENCIO (Avelumab): Merck/Pfizer
Veliparib: AbbVie
Sitravatinib (MGCD516): Mirati Therapeutics/Bristol-Myers Squibb/Beigene
M7824: Merck/GlaxoSmithKline
AMG 510: Amgen
INCMGA00012 (MGA012): Incyte Corporation
Romiplostim: Amgen
TEPMETKO (tepotinib): Merck

Non-Small Cell Lung Cancer (NSCLC) Epidemiology:
The epidemiology section provides insights into historical, current, and forecasted trends in the seven major countries (7MM) from 2019 to 2032. It explores various studies and opinions to recognize the causes of current and forecasted trends. The segmentation includes total prevalence, severity-based prevalence, gender-specific prevalence, and diagnosed cases of episodic and chronic Non-Small Cell Lung Cancer (NSCLC).

Seize Market Opportunities with Our Expert Analysis! Our report delivers valuable insights into market dynamics, key players, and emerging trends @ https://www.delveinsight.com/sample-request/non-small-cell-lung-carcinoma-nsclc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr
Non-Small Cell Lung Cancer (NSCLC) Epidemiology Segmentation:
The Non-Small Cell Lung Cancer (NSCLC) market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
Non-Small Cell Lung Cancer (NSCLC) Total Prevalence
Non-Small Cell Lung Cancer (NSCLC) Prevalent Cases by severity
Non-Small Cell Lung Cancer (NSCLC) Gender-specific Prevalence
Non-Small Cell Lung Cancer (NSCLC) Diagnosed Cases of Episodic and Chronic

Non-Small Cell Lung Cancer (NSCLC) Market Drivers:
Increasing Prevalence of NSCLC
Government Initiatives and Increased Healthcare Spending
Advancements in Precision Medicine
Pipeline of Innovative Drugs

Non-Small Cell Lung Cancer (NSCLC) Market Barriers:
Adverse Side Effects and Drug Resistance
Delayed Diagnosis
Complex Regulatory Approvals
Lack of Access to Healthcare in Low-Income Regions

Stay Ahead in a Competitive Landscape with Our Exhaustive Market Research Report-Dive Into Detailed Analysis, Key Trends, and Future Projections @ https://www.delveinsight.com/sample-request/non-small-cell-lung-carcinoma-nsclc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Scope of the Non-Small Cell Lung Cancer (NSCLC) Market Report:
Study Period: 2019-2032
Coverage: 7MM (The United States, EU5, and Japan)
Key Non-Small Cell Lung Cancer (NSCLC) Companies: Novartis Pharmaceuticals, Novartis Pharmaceuticals, AbbVie, Janssen Pharmaceuticals, Xcovery, Eli Lilly and Company Sanofi, Pfizer, Astellas Pharma/Seattle Genetics, Takeda Pharmaceuticals, Novartis, Merck/Pfizer, Mirati Therapeutics/Bristol-Myers Squibb/Beigene, Merck/GlaxoSmithKline, Amgen, Incyte Corporation.
Key Non-Small Cell Lung Cancer (NSCLC) Therapies: Nazartinib/EGF816, Capmatinib/INC280, Telisotuzumab Vedotin, JNJ-61186372/JNJ-6372, Ensartinib/X-396, Selpercatinib (LY3527723/LOXO-292), SAR408701, Braftovi/encorafinib + Mektovi/binimetinib, PADCEV (enfortumab vedotin/ASG-22ME), TAK-788, Canakinumab/(ACZ885), BAVENCIO (Avelumab), Veliparib, Sitravatinib (MGCD516), M7824, AMG 510, INCMGA00012 (MGA012), Romiplostim, TEPMETKO (tepotinib).
Non-Small Cell Lung Cancer (NSCLC) Therapeutic Assessment: Current marketed and emerging therapies
Non-Small Cell Lung Cancer (NSCLC) Market Dynamics: Non-Small Cell Lung Cancer (NSCLC) Market drivers and Non-Small Cell Lung Cancer (NSCLC) barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Non-Small Cell Lung Cancer (NSCLC) Unmet Needs: Insights into unmet needs, KOL's views, Analyst's views, Market Access, and Reimbursement.

To access the full report and gain a deeper understanding of Non-Small Cell Lung Cancer (NSCLC) market outlook, drug uptake, treatment scenario, and epidemiology trends: https://www.delveinsight.com/sample-request/non-small-cell-lung-carcinoma-nsclc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Table of Content:

1. Key Insights
2. Executive Summary of NSCLC
3. Competitive Intelligence Analysis for NSCLC
4. NSCLC: Market Overview at a Glance
5. NSCLC: Disease Background and Overview
6. Patient Journey
7. NSCLC Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. NSCLC Unmet Needs
10. Key Endpoints of NSCLC Treatment
11. NSCLC Marketed Products
12. NSCLC Emerging Therapies
13. NSCLC: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of NSCLC
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

List of TOP Selling Inhibitors Market Research Report as of 2024:

CTLA-4 Inhibitors Market: https://www.delveinsight.com/report-store/ctla4-inhibitors-market-forecast
VEGF Inhibitors Market: https://www.delveinsight.com/report-store/vegf-inhibitors-market-forecast
TROP-2 Inhibitors Market: https://www.delveinsight.com/report-store/trop2-inhibitors-market-forecast
HER2+ Market: https://www.delveinsight.com/report-store/her2-positive-market-forecast
HER3+ Market: https://www.delveinsight.com/report-store/her3-positive-market-forecast
FTase Inhibitors Market: https://www.delveinsight.com/report-store/ftase-inhibitors-market-forecast
Bispecifics Market: https://www.delveinsight.com/report-store/bispecifics-market-forecast
CAR-T Market: https://www.delveinsight.com/report-store/car-t-market-forecast
CD-19 Market: https://www.delveinsight.com/report-store/cd19-market-forecast
CD-20 Market: https://www.delveinsight.com/report-store/cd20-market-forecast
CD-38 Market: https://www.delveinsight.com/report-store/cd38-market-forecast
TP-53 Market: https://www.delveinsight.com/report-store/tp53-market-forecast
NTRK Market: https://www.delveinsight.com/report-store/ntrk-market-forecast
BRCA Market: https://www.delveinsight.com/report-store/brca-market-forecast
SMAD4/DPC4 Market: https://www.delveinsight.com/report-store/smad4-dpc4-market-forecast
Connective Tissue Growth Factor (CTGF) Inhibitors Market: https://www.delveinsight.com/report-store/connective-tissue-growth-factor-ctgf-inhibitors-market-forecast
Selective Inhibitor of the CXCR4 Chemokine Receptor Market: https://www.delveinsight.com/report-store/selective-inhibitor-of-the-cxcr4-chemokine-receptor-market-forecast
PI3K Market: https://www.delveinsight.com/report-store/pi3k-market-forecast
FGFR Market: https://www.delveinsight.com/report-store/fgfr-market-forecast
PROTAC Market: https://www.delveinsight.com/report-store/protac-market-forecast
CEACAM5 Market: https://www.delveinsight.com/report-store/ceacam5-market-forecast
Anti Cancer Vaccine Market: https://www.delveinsight.com/report-store/anti-cancer-vaccine-market-forecast
Androgen Receptor Inhibitor Market: https://www.delveinsight.com/report-store/androgen-receptor-inhibitor-market-forecast
GnRH Receptor Antagonist Market: https://www.delveinsight.com/report-store/gnrh-receptor-antagonist-market-forecast
CDK4/6 Inhibitor Market: https://www.delveinsight.com/report-store/cdk4-6-inhibitor-market-forecast
SERD Market: https://www.delveinsight.com/report-store/serd-market-forecast
AKT Inhibitor Market: https://www.delveinsight.com/report-store/akt-inhibitor-market-forecast
Radioligand Therapies Market: https://www.delveinsight.com/report-store/radioligand-therapies-market-forecast
B7-H3 Market: https://www.delveinsight.com/report-store/b7-h3-market-forecast
CYP17 Inhibitor Market: https://www.delveinsight.com/report-store/cyp17-inhibitor-market-forecast
NTD AR Inhibitor Market: https://www.delveinsight.com/report-store/ntd-ar-inhibitor-market-forecast
NRG fusion Market: https://www.delveinsight.com/report-store/nrg-fusion-market-forecast
AXL Receptor Tyrosine Kinase Inhibitors Market: https://www.delveinsight.com/report-store/axl-receptor-tyrosine-kinase-inhibitors-market-forecast
PSMA-Targeted Therapy Market: https://www.delveinsight.com/report-store/psma-targeted-therapy-market-forecast
EGFR Market: https://www.delveinsight.com/report-store/egfr-market-forecast
ALK Market: https://www.delveinsight.com/report-store/alk-market-forecast
BRAF Market: https://www.delveinsight.com/report-store/braf-market-forecast
ERBB 2 Receptor Antagonists Market: https://www.delveinsight.com/report-store/erbb2-receptor-antagonists-market-forecast
VEGFR-2 Inhibitor Market: https://www.delveinsight.com/report-store/vegfr2-inhibitor-market-forecast
Thymidine Phosphorylase Inhibitors Market: https://www.delveinsight.com/report-store/thymidine-phosphorylase-inhibitors-market-forecast
DNA Synthesis Inhibitor Market: https://www.delveinsight.com/report-store/dna-synthesis-inhibitor-market-forecast
CD223 Antigen Inhibitors Market: https://www.delveinsight.com/report-store/cd223-antigen-inhibitors-market-forecast
BTK Inhibitors Market: https://www.delveinsight.com/report-store/btk-inhibitors-market-forecast
SERMS Market: https://www.delveinsight.com/report-store/serms-market-forecast
PLK1 Inhibitor Market: https://www.delveinsight.com/report-store/plk1-inhibitor-market-forecast
CD47 Antigen Inhibitors Market: https://www.delveinsight.com/report-store/cd47-antigen-inhibitors-market-forecast
RET Fusion Market: https://www.delveinsight.com/report-store/ret-fusion-market-forecast
ROS-1 Market: https://www.delveinsight.com/report-store/ros1-market-forecast
Mesenchymal-epithelial Transition Factor (MET) Market: https://www.delveinsight.com/report-store/mesenchymal-epithelial-transition-factor-met-market-forecast
MET Kinase Inhibitor Market: https://www.delveinsight.com/report-store/met-kinase-inhibitor-market-forecast

About DelveInsight:
DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.

Contact Information:
Company Name: DelveInsight Business Research LLP
Contact Person: Ram Kapoor
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

This release was published on openPR.